APA
Danese E., Montagnana M., Johnson J. A., Rettie A. E., Zambon C. F., Lubitz S. A., Suarez-Kurtz G., Cavallari L. H., Zhao L., Huang M., Nakamura Y., Mushiroda T., Kringen M. K., Borgiani P., Ciccacci C., Au N. T., Langaee T., Siguret V., Loriot M. A., Sagreiya H., Altman R. B., Shahin M. H. A., Scott S. A., Khalifa S. I., Chowbay B., Suriapranata I. M., Teichert M., Stricker B. H., Taljaard M., Botton M. R., Zhang J. E., Pirmohamed M., Zhang X., Carlquist J. F., Horne B. D., Lee M. T. M., Pengo V., Guidi G. C., Minuz P. & Fava C. (20130116). Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. : Clinical pharmacology and therapeutics.
Chicago
Danese E, Montagnana M, Johnson J A, Rettie A E, Zambon C F, Lubitz S A, Suarez-Kurtz G, Cavallari L H, Zhao L, Huang M, Nakamura Y, Mushiroda T, Kringen M K, Borgiani P, Ciccacci C, Au N T, Langaee T, Siguret V, Loriot M A, Sagreiya H, Altman R B, Shahin M H A, Scott S A, Khalifa S I, Chowbay B, Suriapranata I M, Teichert M, Stricker B H, Taljaard M, Botton M R, Zhang J E, Pirmohamed M, Zhang X, Carlquist J F, Horne B D, Lee M T M, Pengo V, Guidi G C, Minuz P and Fava C. 20130116. Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. : Clinical pharmacology and therapeutics.
Harvard
Danese E., Montagnana M., Johnson J. A., Rettie A. E., Zambon C. F., Lubitz S. A., Suarez-Kurtz G., Cavallari L. H., Zhao L., Huang M., Nakamura Y., Mushiroda T., Kringen M. K., Borgiani P., Ciccacci C., Au N. T., Langaee T., Siguret V., Loriot M. A., Sagreiya H., Altman R. B., Shahin M. H. A., Scott S. A., Khalifa S. I., Chowbay B., Suriapranata I. M., Teichert M., Stricker B. H., Taljaard M., Botton M. R., Zhang J. E., Pirmohamed M., Zhang X., Carlquist J. F., Horne B. D., Lee M. T. M., Pengo V., Guidi G. C., Minuz P. and Fava C. (20130116). Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. : Clinical pharmacology and therapeutics.
MLA
Danese E, Montagnana M, Johnson J A, Rettie A E, Zambon C F, Lubitz S A, Suarez-Kurtz G, Cavallari L H, Zhao L, Huang M, Nakamura Y, Mushiroda T, Kringen M K, Borgiani P, Ciccacci C, Au N T, Langaee T, Siguret V, Loriot M A, Sagreiya H, Altman R B, Shahin M H A, Scott S A, Khalifa S I, Chowbay B, Suriapranata I M, Teichert M, Stricker B H, Taljaard M, Botton M R, Zhang J E, Pirmohamed M, Zhang X, Carlquist J F, Horne B D, Lee M T M, Pengo V, Guidi G C, Minuz P and Fava C. Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. : Clinical pharmacology and therapeutics. 20130116.